Marea Therapeutics has marked a significant milestone with the successful closure of a $190 million combined Series A and B financing, positioning the clinical-stage biotechnology firm to accelerate its pioneering efforts in cardiometabolic disease treatments. Led by Third Rock Ventures and supported by a consortium of leading investors including Sofinnova Investments, Forbion, and Perceptive Xontogeny Venture Fund, the funding underscores growing investor confidence in Marea’s groundbreaking approach.
Founded on a robust foundation of human genetics research, Marea Therapeutics aims to revolutionize cardiovascular care by targeting underlying genetic drivers of metabolic dysfunction. At the forefront of its innovative pipeline is MAR001, a first-in-class ANGPTL4 inhibitor currently advancing through Phase 2 clinical trials. This promising therapy is designed to address elevated remnant cholesterol levels, a critical risk factor for cardiovascular events, by enhancing lipoprotein lipase activity within adipose tissue.
“Today’s funding announcement marks a pivotal moment for Marea Therapeutics as we advance toward realizing our vision of transforming cardiometabolic disease management,” said Dr. Josh Lehrer, M.D., M.Phil., FACC, Chief Executive Officer of Marea. “With this support, we are poised to expand our clinical programs and further explore the potential of MAR001 and our pipeline candidates to redefine therapeutic outcomes for patients.”
Supported by a distinguished team of scientific founders, including renowned experts like Dr. Ethan J. Weiss, M.D., Marea Therapeutics combines deep expertise in genetics and adipocyte biology to pioneer targeted therapies that address the root causes of cardiovascular morbidity. The company’s strategic approach is underpinned by compelling Phase 1 data demonstrating MAR001’s ability to significantly reduce remnant cholesterol levels and improve metabolic biomarkers.
“We are thrilled to partner with Marea Therapeutics as it advances its innovative therapies aimed at reshaping the treatment landscape for cardiometabolic diseases,” commented Dr. Maha Katabi, Ph.D., General Partner at Sofinnova Investments. “The robust investor support underscores confidence in Marea’s scientific prowess and potential to deliver meaningful clinical advancements.”
Moving forward, Marea Therapeutics plans to leverage its strengthened financial position to expand its clinical footprint and advance additional pipeline candidates targeting various nodes of cardiometabolic diseases. With a commitment to rigorous scientific inquiry and patient-centric innovation, the company is poised to redefine standards of care and improve outcomes for patients worldwide. www.mareatx.com. Source: Business Wire
